Methyl 3-hydroxy-4-methoxybenzoate

In its synthetic pathway, this compound provides the substituted benzoate fragment that is elaborated through a series of reactions, including alkylation, nitration, reduction, cyclization, and amination, to construct the quinazoline core essential for Gefitinib’s activity. Through these transformations, the intermediate is converted into the final API, which functions as a tyrosine kinase inhibitor used in the treatment of non‑small cell lung cancer (NSCLC). Methyl 3‑hydroxy‑4‑methoxybenzoate is a key intermediate in the synthesis of the anticancer active pharmaceutical ingredient Gefitinib.